Medicines committee felt unable to recommend use of pentosan polyphosphate in vCJDBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7418.770-b (Published 02 October 2003) Cite this as: BMJ 2003;327:770
- Susan Mayor
Pentosan polysulphate, the drug used for the last eight months to treat a UK teenager with variant Creutzfeldt-Jakob disease (vCJD), was reviewed by the Committee on the Safety of Medicines last year.
In its review (October 2002), the Committee felt unable to recommend its use in vCJD because of the absence of in vitro or in vivo data relevant to vCJD and the lack of information on the basic pharmacology of the drug, including its mode …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial